Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Moreau, Philippe [1 ]
Kumar, Shaji [2 ]
Boccia, Ralph [3 ]
Iida, Shinsuke [4 ]
Goldschmidt, Hartmut [5 ]
Cocks, Kim [6 ]
Zahlten-Kumeli, Anita [7 ]
Yucel, Emre [7 ]
Panjabi, Sumeet [7 ]
Dimopoulos, Meletios [8 ]
机构：
[1] Univ Hosp Hotel Dieu, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] KCStats Consultancy, Leeds, W Yorkshire, England
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷
关键词：
multiple myeloma; carfilzomib; once-weekly; patient-reported outcomes; quality of life;
D O I：
10.1016/j.clml.2018.07.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-138
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [1] Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study ARROW
    Mateos, Maria-Victoria
    Moreau, Philippe
    Berenson, James R.
    Weisel, Katja
    Lazzaro, Antonio
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Huang, Mei
    Zahlten-Kumeli, Anita
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (ARROW) and comparison with ENDEAVOR
    Takezako, Naoki
    Shibayama, Hirohiko
    Handa, Hiroshi
    Hagiwara, Shotaro
    Ozaki, Shuji
    Suzuki, Kenshi
    Kosugi, Hiroshi
    Ri, Masaki
    Sugiura, Isamu
    Choi, Ilseung
    Miyamoto, Toshihiro
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (02) : 219 - 230
  • [3] Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis
    Dimopoulos, Meletios A.
    Niesvizky, Ruben
    Weisel, Katja
    Siegel, David S.
    Hajek, Roman
    Mateos, Maria-Victoria
    Cavo, Michele
    Huang, Mei
    Zahlten-Kumeli, Anita
    Moreau, Philippe
    BLOOD CANCER JOURNAL, 2020, 10 (03)
  • [4] Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study
    Moreau, Philippe
    Mateos, Maria-Victoria
    Berenson, James R.
    Weisel, Katja
    Lazzaro, Antonio
    Song, Kevin
    Dimopoulos, Meletios A.
    Huang, Mei
    Zahlten-Kumeli, Anita
    Stewart, A. Keith
    LANCET ONCOLOGY, 2018, 19 (07): : 953 - 964
  • [5] Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludek
    Weisel, Katja
    Coriu, Daniel
    Obreja, Michaela
    Goldrick, Amanda
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S332 - S333
  • [6] Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludek
    Weisel, Katja
    Coriu, Daniel
    Obreja, Mihaela
    Goldrick, Amanda
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E266 - E267
  • [7] A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly
    Leleu, Xavier
    Chari, Ajai
    Richard, Shambavi
    Khurana, Monica
    Yusuf, Akeem
    Usmani, Saad Z.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1049 - 1058
  • [8] Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludk
    Weisel, Katja
    Coriu, Daniel
    Obreja, Mihaela
    Goldrick, Amanda
    Dimopoulos, Meletios A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S16 - S16
  • [9] Real-World Use of Carfilzomib for the Treatment of Relapsed/Refractory Multiple Myeloma in Germany: Once-Weekly and Twice-Weekly Administration Schedules
    Trautmann-Grill, Karolin
    Kossack, Nils
    El Hadad, Laila
    Najafi, Bahar
    Kaehm, Katharina
    Boehm, Doris
    Papkalla, Armin
    Pignot, Marc
    Samuel, Amir
    Katz, Jessica
    Dhamane, Amol D.
    BLOOD, 2024, 144 : 7826 - 7827
  • [10] ARROW2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Dimopoulos, Meletios A.
    Coriu, Daniel
    Delimpasi, Sosana
    Spicka, Ivan
    Upchurch, Terry
    Fang, Belle
    Talpur, Rakhshandra
    Faber, Edward
    Beksac, Meral
    Leleu, Xavier
    BLOOD ADVANCES, 2024, 8 (19) : 5012 - 5021
12345